UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 22,078 shares, an increase of 8,231.3% from the May 14th total of 265 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 59,267 shares, the days-to-cover ratio is presently 0.4 days.

UCB Stock Performance

OTCMKTS:UCBJY traded up $1.58 during trading on Tuesday, reaching $151.74. The company’s stock had a trading volume of 18,290 shares, compared to its average volume of 37,792. The firm has a 50 day moving average of $145.27 and a 200-day moving average of $146.65. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. UCB has a 12 month low of $89.00 and a 12 month high of $168.76.

Analyst Ratings Changes

UCBJY has been the subject of several research analyst reports. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 13th. Wolfe Research upgraded shares of UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, UCB presently has an average rating of “Buy”.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.